Giá hiện tại
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germ...|
e.g. Promoter holding
Loading chart...
Dự báo EPS và doanh thu theo đồng thuận của các nhà phân tích.
Dữ liệu dự báo lợi nhuận cho công ty này hiện không có.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | UUtah Medic... | UTMD | $204.92M | 21.55 | 1.66 | 30.50% | 34.30% | 8.81% | -12.10% |
| 2. | PPro-Dex In... | PDEX | $210.11M | 18.09 | 4.25 | 15.10% | 16.80% | 26.50% | 11.00% |
| 3. | NNephros In... | NEPH | $33.15M | 17.94 | 2.64 | 8.85% | 8.48% | 17.00% | 18.00% |
| 4. | EEmbecta Co... | EMBC | $366.02M | 4.40 | 2.61 | 8.59% | 23.30% | — | -8.10% |
| 5. | MMeihua Int... | MHUA | $425.43M | 0.25 | 0.05 | 10.30% | 8.53% | 5.90% | -16.20% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Quarter (M) | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Mar 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 2.92 | 6.32 | 1.17 | 2.53 | -3.13 | 5.01 | 2.03 | 4.74 |
COGS | 0.97 | 2.1 | 0.18 | 0.39 | 0.18 | 0.38 | 0.38 | 0.88 |
Gross Profit | 1.96 | 4.23 | 0.99 | 2.14 | -2.6 | 4.62 | 1.66 | 3.86 |
Gross Profit % | 66.85% | 66.85% | 84.55% | 84.55% | 82.96% | 92.32% | 81.49% | 81.49% |
| 0.16 | 0.34 | 1.79 | 3.87 | -0.69 | 0.95 | 0.45 | 1.06 | |
EBIT | 1.8 | 3.89 | -0.8 | -1.74 | -1.91 | 3.68 | 1.2 | 2.8 |
OPM % | 61.51% | 61.51% | -68.64% | -68.64% | 61.03% | 73.45% | 59.09% | 59.09% |
Non-Operating Income | -0 | -0 | 0.19 | 0.41 | -0.18 | 0.47 | 0.1 | 0.24 |
PBT | 1.8 | 3.89 | -0.61 | -1.32 | -2.09 | 4.15 | 1.3 | 3.04 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | 1.8 | 3.89 | -0.61 | -1.32 | -2.09 | 4.15 | 1.3 | 3.04 |
NPM % | 61.48% | 61.48% | -52.4% | -52.4% | 66.67% | 82.84% | 64.14% | 64.14% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
Revenue | 4.43 | 23.54 | 6.71 | 8.19 | 8.65 |
COGS | 1.89 | 10.98 | 3.35 | 2.3 | 1.1 |
Gross Profit | 2.54 | 12.56 | 3.36 | 5.89 | 7.54 |
Gross Profit % | 57.4% | 53.36% | 50.07% | 71.9% | 87.24% |
| 0.09 | 2.37 | 1.4 | 3.89 | 1.78 | |
EBIT | 2.46 | 10.2 | 1.96 | 2 | 5.77 |
OPM % | 55.46% | 43.3% | 29.22% | 24.38% | 66.7% |
Non-Operating Income | 0.08 | -0.18 | 0.29 | 0.38 | 0.64 |
PBT | 2.54 | 10.01 | 2.25 | 2.37 | 6.4 |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - |
Net Income | 2.54 | 10.01 | 2.25 | 2.37 | 6.4 |
NPM % | 57.26% | 42.52% | 33.58% | 28.99% | 74.06% |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| 4.18 | 7.1 | 9.69 | 11.76 | 7.77 | |
| 0 | 1.57 | 0 | 0 | 4.13 | |
| 0 | 0 | 0 | 0 | 0 | |
| 0.73 | 5.27 | 6.06 | 6.77 | 18.34 | |
| 0 | 0.02 | 0.06 | 0.39 | 0 | |
Total Assets | 4.92 | 13.96 | 15.81 | 18.92 | 30.24 |
| 0 | 0 | 0.01 | 0.01 | 0.01 | |
| 2.54 | 12.55 | 14.8 | 17.18 | 30.14 | |
| 0 | 0 | 0 | 0 | 0 | |
| 1.89 | 1.41 | 0.99 | 1.73 | 0.09 | |
| 0.49 | 0 | 0 | 0 | 0 | |
Total Liabilities | 4.92 | 13.96 | 15.81 | 18.92 | 30.24 |
Số liệu hợp nhất (triệu) / Có thể xem riêng lẻ
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| 4.18 | 4.45 | 0.9 | 2.08 | -6.74 | |
| 0 | -1.53 | 1.73 | 0.34 | -4.2 | |
| 0 | 0 | -0.04 | -0.34 | 6.95 | |
Net CFNet Cash Flow | 4.18 | 2.92 | 2.59 | 2.07 | -3.99 |
FCFFree Cash Flow | 4.18 | 4.45 | 0.9 | 2.08 | -6.74 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| - | 132.7% | 16.5% | 14.8% | 27.0% | |
| - | - | - | - | - | |
| 2.07 | 9.88 | 15.86 | 10.71 | 344.31 | |
| - | 2.49 | 0.45 | 0.47 | 0.35 | |
Cash Conversion | 1.65 | 0.44 | 0.40 | 0.88 | -1.05 |
Payout Ratio | - | - | - | - | - |
| - | 431.7% | -71.5% | 21.9% | 5.6% | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| 4.00 | 6.00 | 5.00 | 6.00 | 5.00 | |
| - | 1.90 | 1696.14 | -1.53 | 1.59 | |
| 100.00 | 66.67 | 60.00 | 73.33 | 66.67 | |
| 0.6% | 0.4% | 0.3% | 0.3% | 0.7% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Ai sở hữu Anbio Biotechnology - Class A, theo hồ sơ SEC
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 33,299 | +7.0% | 1.00 | |
| 15 Oct 2026 | 31,124 | -42.4% | 1.00 | |
| 30 Sep 2026 | 54,022 | +4.5% | 1.00 | |
| 15 Sep 2026 | 51,672 | -11.6% | 1.00 | |
| 31 Aug 2026 | 58,423 | +122.9% | 1.00 | |
| 14 Aug 2026 | 26,210 | -44.9% | 1.00 | |
| 31 Jul 2026 | 47,525 | +50.5% | 1.23 | |
| 15 Jul 2026 | 31,583 | -64.6% | 1.00 | |
| 30 Jun 2026 | 89,295 | +0.8% | 1.40 | |
| 15 Jun 2026 | 88,550 | +1.3% | 2.47 | |
| 29 May 2026 | 87,425 | -5.6% | 3.91 | |
| 15 May 2026 | 92,563 | +111.7% | 4.18 | |
| 30 Apr 2026 | 43,717 | -16.3% | 1.62 | |
| 15 Apr 2026 | 52,247 | +71.3% | 1.91 | |
| 31 Mar 2026 | 30,509 | -15.2% | 1.14 | |
| 13 Mar 2026 | 35,977 | -26.9% | 1.00 | |
| 27 Feb 2026 | 49,220 | -5.7% | 1.00 | |
| 13 Feb 2026 | 52,199 | -30.6% | 1.00 | |
| 30 Jan 2026 | 75,266 | +46.6% | 1.02 | |
| 15 Jan 2026 | 51,351 | +9.3% | 1.44 | |
| 31 Dec 2025 | 46,969 | -5.1% | 1.22 | |
| 15 Dec 2025 | 49,516 | -15.4% | 1.38 | |
| 28 Nov 2025 | 58,535 | -12.4% | 3.66 | |
| 14 Nov 2025 | 66,844 | -35.6% | 1.29 |
FINRA consolidated short interest, reported twice a month for every US listing.
Hồ sơ SEC và bản ghi cuộc gọi kết quả kinh doanh của Anbio Biotechnology - Class A
What recent news says about Anbio Biotechnology - Class A, scored for sentiment.